Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: A 12-month randomized prospective study Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Tomography, Optical Coherence
  • Wet Macular Degeneration

abstract

  • Fixed-interval and variable dosing regimens of intravitreal bevacizumab improved visual acuity and anatomic outcomes after 12 months in eyes with neovascular AMD. However, variable dosing had a reduced treatment burden. Larger trials are needed to confirm these results.

publication date

  • March 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ajo.2011.08.018

PubMed ID

  • 22014603

Additional Document Info

start page

  • 481

end page

  • 489.e1

volume

  • 153

number

  • 3